Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuros BiosciencesCSBTF 77 3-Year Book Growth Rate is 4.60% as of Jun. 2026. GuruFocus rates CSBTF with a GF Score™ of 77/100 and a GF Value™ of $46.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 57.5% on this metric.
During the past 12 months, Kuros Biosciences's average Book Value per Share Growth Rate was 26.90% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -5.70% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -15.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Kuros Biosciences was 26.60% per year. The lowest was -50.80% per year. And the median was -19.40% per year.
Kuros Biosciences (OTCPK:CSBTF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Kuros Biosciences 3-Year Book Growth Rate Related Terms
CSBTF vs ABT, SYK, MDT: 3-Year Book Growth Rate Comparison
For the Medical Devices subindustry, Kuros Biosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's 3-Year Book Growth Rate falls into.
Kuros Biosciences 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 4.60% mean?
Kuros Biosciences (CSBTF) has a 3-Year Book Growth Rate of 4.60% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #323 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 42.5%.
Is Kuros Biosciences' 3-Year Book Growth Rate too high?
Kuros Biosciences' current 3-Year Book Growth Rate is 4.60%. The Medical Devices & Instruments industry median 3-Year Book Growth Rate is 2.35. Kuros Biosciences' value of 4.60% is 95.7% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #323 out of 760 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' 3-Year Book Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #323 out of 760 companies for 3-Year Book Growth Rate. This puts Kuros Biosciences in the upper half of its industry. The industry median 3-Year Book Growth Rate is 2.35. Kuros Biosciences' value of 4.60% is 95.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.35, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current 3-Year Book Growth Rate of 4.60% is 95.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current 3-Year Book Growth Rate is 4.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $46.72, compared to a current price of $26.99 — trading 42.2% below its estimated fair value. The current 3-Year Book Growth Rate is 4.60% and 95.7% above the Medical Devices & Instruments industry median of 2.35. Kuros Biosciences' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current 3-Year Book Growth Rate is 4.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $26.99 is trading 42.2% below its estimated GF Value™ of $46.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
3-Year Book Growth Rate: 4.60%
GF Value™: $46.72 vs. price of $26.99 (42.2% below fair value)
Industry Position: 95.7% above the Medical Devices & Instruments median (#323 of 760)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
77GF Score
Get the complete analysis for CSBTF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
